martes, 17 de noviembre de 2026

Pharmacokinetics in Patients with Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosing September 2026 (++++)

https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pharmacokinetics-patients-impaired-hepatic-function-study-design-data-analysis-and-impact-dosing?utm_medium=email&utm_source=govdelivery Today, the U.S. Food and Drug Administration (FDA) published the guidance snapshot and podcast for the draft guidance “Pharmacokinetics in Patients with Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosage.” FDA’s Guidance Snapshot Pilot Program aims to increase the public’s awareness of key regulatory topics and current scientific thinking. The pilot program intends to boost engagement with FDA guidance documents and elicit constructive feedback to improve the design and application of recommendations. The snapshot highlights key points in the guidance document in plain language and is not a substitute for the guidance document. The podcast provides highlights and background for the guidance through a conversation with FDA staff. Liver disease can lead to changes in a drug’s pharmacokinetics to a degree necessitating different recommendations for use of the drug in patients with hepatic impairment. This draft guidance is intended to provide recommendations to sponsors and applicants who plan to conduct studies to assess the influence of hepatic impairment on the pharmacokinetics, and, where appropriate, pharmacodynamics of a drug, including therapeutic biological products. https://www.fda.gov/drugs/guidances-drugs/guidance-snapshot-pilot?utm_medium=email&utm_source=govdelivery Pharmacokinetics in Patients with Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosage Draft Guidance for Industry https://www.fda.gov/media/196860/download?attachment=&utm_medium=email&utm_source=govdelivery Guidance Recap Podcast | Pharmacokinetics in Patients with Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosage https://www.fda.gov/drugs/guidances-drugs/guidance-recap-podcast-pharmacokinetics-patients-impaired-hepatic-function-study-design-data?utm_medium=email&utm_source=govdelivery

Vapes, pouches and now tablets: The tobacco industry’s newest nicotine product worries public health advocates The makers of Zyn Melts and Perlz say they’re for adults. But experts worry their resemblance to mints could make them appealing to kids. by Kathryn Kranhold

https://www.theexamination.org/articles/zyn-melts-nicotine-tablets-kids?utm_source=stat&utm_medium=referral&utm_campaign=syndication The latest product from the tobacco industry is a flavorful nicotine tablet that melts in your mouth, allowing users to get a buzz as discreetly as popping a mint — and amping up concerns that products to replace cigarettes are too appealing to kids and teens.

Abortion in the United States Dashboard

https://www.kff.org/womens-health-policy/abortion-in-the-u-s-dashboard/ The Abortion in the U.S. Dashboard is an ongoing research project tracking state abortion policies and litigation following the overturning of Roe v. Wade. On June 24, 2022, the Supreme Court overturned Roe v. Wade, eliminating the federal constitutional standard that had protected the right to abortion. Without any federal standard regarding abortion access, states will set their own policies to ban or protect abortion. The Abortion in the United States Dashboard is an ongoing research project tracking state abortion policies and litigation following the overturning of Roe v. Wade.

Federal judge issues final ruling blocking U.S. plan to limit visa length for grad students, postdocs Research advocates worried plan would be major obstacle for international researchers

https://www.statnews.com/2026/11/16/judge-rejects-visa-limits-international-researchers-upholds-duration-of-status-policy/ By Anil OzaNov. 16, 2026 General Assignment Reporter

The problem with ‘zero tolerance for bad behavior’ signs at hospitals Research suggests the signs don’t reduce violence against health care workers

https://www.statnews.com/2026/11/17/hospital-signs-violence-health-care-workers-research-stigma/ By Autumn Fiester, Aliza Narva, and Stacy C. SmithNov. 17, 2026 Fiester is professor of medical ethics and health policy at the University of Pennsylvania’s Perelman School of Medicine and director of the Penn Program in Clinical Conflict Management. Narva is the director of ethics at the Hospital of the University of Pennsylvania. Smith is a registered nurse, certified health care ethics consultant, and qualitative researcher.

New Trump regulation promises to crush ‘fraudsters.’ All the savings come from Medicare Advantage New rule would reissue Biden-era regulations to pursue audits of MA plans

https://www.statnews.com/2026/11/16/cms-proposes-more-agressive-audits-medicare-advantage-crush/ By Bob HermanNov. 16, 2026 Business of Health Care Reporter

Moving to a New State? Your Healthcare Might Get More Complicated By Katherine Ruppelt, Nashville Public Radio, Cara Anthony, and Blake Farmer, Nashville Public Radio Nov. 17, 2026

https://kffhealthnews.org/insurance/healthq-moving-new-state-new-healthcare-access-insurance/?utm_campaign=KHN%3A%20First%20Edition&utm_medium=email&_hsenc=p2ANqtz--V6zZjzc5PkheoHnqdl0ufsRL_-OWsJj84XXXrKlArLjHdIBpcRZ0wI8e2DSnGV4Ck6NVW0ozwu82IYm3l1uJMVHpYzQ&_hsmi=449750599&utm_content=449750599&utm_source=hs_email KFF Health News: Moving To A New State? Your Healthcare Might Get More Complicated Jael Samano’s recent move from Illinois to Wisconsin after college changed a lot of things in her life. It brought a new job as an environmental consultant and a new housing situation — living on her own for the first time. Those were expected changes. But it wasn’t until she saw her therapist, shortly before moving, that she realized how relocating out of state would also change her healthcare. She’d have to find new providers and learn a new health insurance system through her employer. (Ruppelt, Anthony and Farmer, 11/17)